Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

CALD is an inflammatory demyelinating disease that causes severe motor and cognitive deficit leading to rapid death. Hematopoietic stem cell transplantation (HSCT) can halt neuroinflammation in CALD through the replacement of microglia (i.e., brain immune system) but only if performed during its early phase.

Using standard brain MRI, it is estimated that only 30% of adult CALD patients are identified. Complex and lengthy clinical evaluations together with MRI reading from experts improve CALD detection but are not available in routine clinical practice.

Diffusion tensor imaging is a quantitative microstructural technique that can identify neuroinflammation at a very early stage. Still, its implementation in clinical practice has been very limited due to high inter-center measurements variability and bias due to data quality issues. The approach we will use solves these problems by introducing an automatic calibration and standardization with systematic quality control enabling the use of all MRI scanners in clinical settings.

The innovative aspect of this project lies on the validation of an expert-independent prognosis biomarker able to specifically identify patients at high-risk to convert to CALD so that treatment can be initiated at the early stage of neuroinflammation.

We aim to demonstrate that this tool has at least a 2-fold sensitivity compared to the current standard of care.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

> 18 years old

Male gender

Genetically diagnosed with ALD by carrying an ABCD1 pathogenic variant

Signed written informed consent

Disqualifiers

Patient with non-arrested CALD

Other neurological conditions such as brain tumour, stroke or a traumatic head injury

Contraindication to MRI (claustrophobia, implanted metal components in the head, panic disorder, epilepsy)

People under legal protection measure (tutorship, curatorship or safeguard measures)

Trial population

Adult males carrying an ABCD1 pathogenic variant

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • brainQuant module of brainTale-care platform

    Device

    brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Patients1 intervention
Group B: Healthy volunteers0 interventions

Trial outcomes

Primary outcomes

1

Sensitivity of RD-index19 change of at least 1 point between two consecutive annual measurements to diagnose CALD before or at the same time than the reference diagnostic made by an expert committee

The expert committee comprising 3 experts in neuroradiology blinded to the RD-index19 change results. The study aims to demonstrate that RD-index19-change of at least 1 point between two consecutive annual measurements has a sensitivity significantly greater than 60% to detect CALD conversion before or at the same time as the best experts in the field of CALD diagnosis.

Time frame
1 year, 2 years, 3 years
2

Specificity of RD-index19 change of at least 1 point between two consecutive annual measurements with repect to CALD conversion before or at the same time than the reference diagnostic made by an expert committee

The expert committee comprising 3 experts in neuroradiology blinded to the RD-index19 change results. The study aims to demonstrate that RD-index19-change of at least 1 point between two consecutive annual measurements has a specificity significantly greater than 80% with repect to CALD conversion before or at the same time as the best experts in the field of CALD diagnosis.

Time frame
1 year, 2 years, 3 years

Secondary outcomes

1

Sensitivity values of plasma NfL with regard to CALD diagnosis

Time frame
1 year, 2 years, 3 years
2

Specificity values of plasma NfL with regard to CALD diagnosis

Time frame
1 year, 2 years, 3 years
3

Sensitivity values of FA-index19-change with regard to CALD diagnosis

Time frame
1 year, 2 years, 3 years
4

Specificity values of FA-index19-change with regard to CALD diagnosis

Time frame
1 year, 2 years, 3 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: